Tahir Amin, DipLP, co-founder and director of intellectual property of Initiative for Medicines, Access, and Knowledge, discusses how settlements can impact patient access to biosimilars.
Transcript:
What is a “pay-for-delay” strategy, and what effect does it have on generic drugs or biosimilars reaching patients?
So using the Humira example, Amgen recently tried to come into the marketplace with its own biosimilar, and has now settled with AbbVie rather than go through the whole litigation process. Rumor has it that Amgen won’t get into the market until 2023, whereas it could’ve potentially come into the market now. So that’s a classic example of a settlement where litigation is involved.
Today, since the Supreme Court ruling on “pay-for-delay” settlements, we don’t see as many that are coming through, but there are other types of settlements which are happening [that] we don’t know the terms and conditions of. It might not involve money, but it may involve some other incentives or some other payback in a different way which may not be monetary, but could be other ways; we may give you another market but don’t come into the [United States]—it could be various things.
Ultimately, these deals are actually designed to maintain the maximum profit for the brand holder, the patent holder, and give some kind of exclusivity to whoever they’re settling with, but it doesn’t open the market. It allows the control of the marketplace which unfortunately all falls back on the payer and the public.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.